Clinica Universidad de Navarra

Running trials

• Not yet recruiting

  An international study evaluating diagnostic and theranostic agents in patients with solid tumors and brain metastases.

  2025-523824-39-01· Phase 2· Medica Scientia Innovation Research S.L.· Source

• Not yet recruiting

  Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project)

  NCT07788664· Phase 2· Vall d'Hebron Institute of Oncology· Source

• Not yet recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

  NCT07728188· Phase 3· AbbVie· Source

• Not yet recruiting

  A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis

  2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

  NCT07781644· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Recruiting

  To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

  NCT07629583· Phase 1· Genentech, Inc.· Source

• Not yet recruiting

  Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

  NCT07901868· Phase 2· PETHEMA Foundation· Source

• Not yet recruiting

  A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy

  2026-527617-29-00· Phase 3· Systimmune Inc.· Source

• Not yet recruiting

  A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma

  NCT07192471· Phase 1· Kyowa Kirin Inc.· Source

• Recruiting

  A Study of RO7871996 in Participants with Systemic Lupus Erythematosus

  2026-527221-35-00· Phase 1/2· F. Hoffmann-La Roche AG· Source

• Recruiting

  Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

  2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Revolution Medicines Inc.· Source

• Not yet recruiting

  A Study Comparing Whole-Body Heat Treatment Plus Systemic Therapy to Systemic Therapy Alone, for Advanced Pancreatic Cancer

  NCT07711067· Phase 2/3· ElmediX· Source

• Not yet recruiting

  Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma

  2026-526352-31-00· Phase 2· Fundacion PETHEMA· Source

• Recruiting

  A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

  NCT07751991· Phase 1· Charm Therapeutics· Source

• Recruiting

  Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis

  NCT07799116· Phase 1/2· Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz· Source

• Recruiting

  A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  2026-526654-14-01· Phase 3· Janssen Cilag International· Source

• Recruiting

  A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  NCT07701941· Phase 1/2· Daiichi Sankyo· Source

• Not yet recruiting

  A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies

  NCT07719348· Phase 1/2· Servier· Source

• Recruiting

  A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.

  2025-523285-25-00· Phase 3· AstraZeneca AB· Source

• Not yet recruiting

  A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer

  2026-527365-30-00· Phase 1/2· Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer· Source

• Not yet recruiting

  A study to learn about the effects of Trontinemab in participants at risk for Alzheimer‘s disease

  2025-524314-29-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

  NCT07564141· Phase 3· Genmab· Source

• Not yet recruiting

  Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.

  2026-525883-17-00· Phase 3· Genmab A/S· Source

• Recruiting

  A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

  NCT07636811· Phase 2· Alnylam Pharmaceuticals· Source

• Not yet recruiting

  A Study to Evaluate the Efficacy and Safety of CP-012B in Participants With Parkinson’s Disease With Early Morning OFF Episodes

  2026-526634-46-00· Phase 2· Contera Pharma A/S· Source

• Recruiting

  Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)

  NCT07864207· Phase 1/2· IDP Discovery Pharma S.L.· Source

• Active, not recruiting

  Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma

  2023-510560-12-00· Phase 2· Fundacion Pethema· Source

• Recruiting

  A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

  2026-525234-39-00· Phase 1· Janssen Cilag International· Source

• Recruiting

  Phase 1/2 multicenter, two-arms, open-label, dose-escalation study of IDP-121 in combination with chemotherapy in patients with relapsed small cell lung cancer (SCLC) (MYCrocytic)

  2025-521902-17-00· Phase 1/2· Idp Discovery Pharma S.L.· Source

• Recruiting

  Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation

  NCT07575269· Boston Scientific Corporation· Source

• Recruiting

  A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma

  2025-523815-12-00· Phase 3· Janssen Cilag International· Source

• Not yet recruiting

  Optimizing the Use of Aspirin for the Prevention of Preeclampsia

  NCT07665853· Phase 3· Hospital Universitari Vall d'Hebron Research Institute· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

  NCT07581002· Phase 2/3· AbbVie· Source

• Recruiting

  A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer

  2025-522818-23-00· Phase 3· Zai Lab (US) LLC· Source

• Recruiting

  Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07284602· Phase 3· PureTech· Source

• Recruiting

  Grass Immunotherapy for Rhinitis and Asthma (GIRA)

  2025-521736-10-00· Phase 3· LETI Pharma S.L.U.· Source

• Recruiting

  Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES)

  2025-521709-42-00· Phase 3· LETI Pharma S.L.U.· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  NCT07555938· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease

  2025-524001-33-00· Phase 2· Immunovant Sciences GmbH· Source

• Recruiting

  Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07562152· Phase 3· Immuneering Corporation· Source

• Recruiting

  A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

  NCT07629960· Phase 1/2· Blueprint Medicines Corporation· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Multi-centre Phase 1/2 study testing LB-208 for adults with relapsed/refractory AML or high-risk MDS

  2025-523396-38-00· Phase 1/2· Aop Orphan Pharmaceuticals GmbH· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma

  2025-524014-29-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

  NCT07614776· Phase 3· Amgen· Source

• Recruiting

  A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  NCT07393282· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

  NCT07570173· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

  NCT07582432· Phase 3· Grifols Biologicals, LLC· Source

Showing 50 of 435.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer50 recruiting
• Multiple myeloma40 recruiting
• Ovarian cancer40 recruiting
• Pancreatic cancer23 recruiting
• Prostate cancer22 recruiting
• Colorectal cancer21 recruiting
• Acute myeloid leukaemia20 recruiting
• Liver and biliary tract cancer18 recruiting
• Childhood cancers17 recruiting
• Myelodysplastic syndromes17 recruiting
• Metastatic breast cancer15 recruiting
• Gastric and oesophageal cancer12 recruiting
• Lupus (SLE)12 recruiting
• Hodgkin lymphoma11 recruiting
• Triple-negative breast cancer11 recruiting
• Bladder cancer10 recruiting
• Chronic lymphocytic leukaemia10 recruiting
• Endometrial cancer9 recruiting
• Head and neck cancer9 recruiting
• Dermatomyositis and polymyositis (myositis)8 recruiting
• Diffuse large B-cell lymphoma8 recruiting
• Follicular lymphoma8 recruiting
• Immune thrombocytopenia (ITP)7 recruiting
• Chronic myeloid leukaemia6 recruiting
• Melanoma6 recruiting
• Alzheimer disease5 recruiting
• Graves' disease and hyperthyroidism4 recruiting
• IgA nephropathy4 recruiting
• Kidney cancer4 recruiting
• Mantle cell lymphoma4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Amyloidosis3 recruiting
• Chronic kidney disease3 recruiting
• COPD3 recruiting
• Macular degeneration3 recruiting
• Parkinson disease3 recruiting
• Asthma2 recruiting
• Atrial fibrillation2 recruiting
• Bronchiectasis2 recruiting
• Cystic fibrosis2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Mesothelioma2 recruiting
• Neuroendocrine tumours2 recruiting
• Rheumatoid arthritis2 recruiting
• Sarcoma2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Depression1 recruiting
• Down syndrome1 recruiting
• Essential tremor1 recruiting
• Glioblastoma1 recruiting
• Hearing loss1 recruiting
• High blood pressure1 recruiting
• Myasthenia gravis1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Obesity1 recruiting
• Primary biliary cholangitis1 recruiting
• Schizophrenia1 recruiting
• Thyroid cancer1 recruiting

Closed trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

  NCT07224672· Phase 2· GlaxoSmithKline· Source

• Completed

  A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC

  2025-522867-13-00· Phase 2· Merus B.V.· Source

• Recruiting

  A Phase IIb study to evaluate the effect of combination of dapagliflozin and baxdrostat compared with baxdrostat alone in participants with chronic kidney disease and high blood pressure

  2025-522407-23-00· Phase 2· AstraZeneca AB· Source

• Withdrawn

  Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

  NCT07353957· Phase 2· Genmab· Source

• Completed

  A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease

  2024-516966-12-00· Phase 2· Novartis Pharma AG· Source

• Recruiting

  A Phase 1/2a Study of UCART20x22 in B-Cell Non-Hodgkin Lymphoma [NatHaLi-01]

  NCT05607420· Phase 1/2· Cellectis· Source

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· Phase 3· Incyte Corporation· Source

• Completed

  Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)

  NCT06984328· Phase 2· Genmab A/S· Source

• Completed

  A study of AZD2962, an IRAK4 inhibitor, in Participants with Haematologic Neoplasms

  2025-520786-44-00· Phase 1/2· AstraZeneca AB· Source

• Completed

  A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors

  NCT04892017· Phase 1/2· Deciphera Pharmaceuticals Inc.· Source

• Completed

  A trial to learn how safe AZD0022 is, how well it works, and how it moves throughout the body over time in adults with tumors that have a KRAS-G12D mutation, when given alone and with other cancer drugs

  NCT06599502· Phase 1/2· AstraZeneca AB· Source

• Completed

  Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)

  NCT05828303· Phase 1· Bristol-Myers Squibb Services Unlimited Company· Source

• Completed

  A trial to learn how well NMS-01940153E works in combination with atezolizumab and priming administration of decitabine or with atezolizumab alone in patients with hepatocellular carcinoma (HCC) that cannot be removed by surgery and who received prior treatment with other anti-cancer medicines

  2024-516737-12-00· Phase 2· Nerviano Medical Sciences S.r.l.· Source

• Completed

  Effect of a Postbiotic Intake on Glucose Control and Microbiota Composition of Type 2 Diabetic Subjects: a Randomized Controlled Trial.

  NCT06448182· Clinica Universidad de Navarra, Universidad de Navarra· Source

• Active, not recruiting

  A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

  NCT06604715· Phase 1· Janssen Research & Development, LLC· Source

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia

  2024-511057-22-00· Phase 3· Janssen Cilag International· Source

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

  NCT06534411· Phase 3· Novo Nordisk A/S· Source

• Terminated

  A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

  NCT06516510· Early phase 1· Blue Earth Therapeutics Ltd· Source

• Completed

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Effect of Copper CU64 PSMA I&T scanning to detect potential disease spread to lymph nodes in men with newly diagnosed Prostate Cancer

  2024-512754-16-01· Phase 3· Curium US LLC· Source

• Terminated

  LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)

  NCT06558799· Phase 2· NovoCure GmbH· Source

• Active, not recruiting

  RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

  NCT06243458· Phase 2· GCP-Service International West GmbH· Source

• Completed

  FOCALFLEX (CE Mark) Study

  NCT06271967· Abbott Medical Devices· Source

• Completed

  Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/​Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody

  NCT04309981· Phase 2· Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer· Source

• Completed

  Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia

  2023-508819-23-00· Phase 1· Hutchmed Ltd.· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source

• Completed

  A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1

  NCT05870748· Phase 2· Sutro Biopharma Inc.· Source

• Active, not recruiting

  ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

  NCT06328738· Phase 1· Enliven Therapeutics· Source

• Completed

  A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

  NCT06384547· Phase 3· Viridian Therapeutics, Inc.· Source

• Completed

  A Phase 2 Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Previously Treated with Trastuzumab Deruxtecan

  NCT05954143· Phase 2· Bolt Biotherapeutics Inc.· Source

• Completed

  EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases

  NCT06392828· IMDEA Food· Source

• Completed

  Feasibility Study on the FARAVIEW Technology

  NCT06175234· Boston Scientific Corporation· Source

• Withdrawn

  The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

  NCT06291415· Phase 1· Hutchmed· Source

• Completed

  NXP800 in subjects with Ovarian Cancer

  NCT05226507· Phase 1· Nuvectis Pharma Inc.· Source

• Completed

  A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

  NCT06323928· Phase 2· H. Lundbeck A/S· Source

• Completed

  Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

  NCT06241313· Phase 3· AbbVie· Source

• Completed

  Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

  NCT06119217· Phase 2· Trishula Therapeutics, Inc.· Source

• Completed

  A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors

  NCT05109975· Phase 1· Debiopharm International S.A.· Source

• Completed

  A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

  2023-506092-10-00· Phase 2· Ascendis Pharma Oncology Division A/S· Source

• Completed

  A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)

  2023-509472-42-00· Phase 3· Celgene International II S.a.r.l.· Source

• Completed

  GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

  2022-502453-33-00· Phase 2· Genmab A/S· Source

• Completed

  THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICAL CONTROL IN HIGH-RISK GOLD B PATIENTS (B+)

  2023-507304-32-00· Phase 4· Fundacio Privada Mon Clinic Barcelona· Source

• Terminated

  Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

  NCT06268574· Phase 2· Ryvu Therapeutics SA· Source

• Completed

  A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia with or without NPM1 Mutation (RIVER-52)

  2023-505910-10-00· Phase 2· Ryvu Therapeutics S.A.· Source

• Completed

  Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN

  2023-505796-76-00· Phase 1· Merck Healthcare KGaA· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

  NCT06224348· Phase 3· Sanofi· Source

• Completed

  (VELA) Study of BLU-222 in Advanced Solid Tumors

  NCT05252416· Phase 1/2· Blueprint Medicines Corp.· Source

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Regeneron Pharmaceuticals· Source

• Completed

  A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma

  2023-503689-21-00· Phase 1/2· F. Hoffmann-La Roche AG· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

  NCT06113445· Phase 3· Incyte Corporation· Source

Showing 50 of 219.

Conditions

Diseases this institution publishes on or runs trials for.

• Multiple myeloma88 works · 95 trials
• Ovarian cancer37 works · 53 trials
• Migraine17 works · 5 trials
• Diffuse large B-cell lymphoma9 works · 16 trials
• Myelodysplastic syndromes7 works · 23 trials
• Follicular lymphoma6 works · 13 trials